Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425191
Status:
COMPLETED
Last Update Posted:
2009-12-07
First Post:
2007-01-19
Brief Title:
Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
Sponsor:
Sanofi
Organization:
Sanofi
Study Overview
Official Title:
A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel and Gemcitabine and of CisplatinGemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2009-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the antitumour activity response rate in patients with locally advanced or metastatic non-small cell lung cancer NSCLC of two different combinations of docetaxel and gemcitabine and of a sequential treatment of cisplatin gemcitabine followed by docetaxel as first line chemotherapy To evaluate the quantitative and qualitative toxicity of each treatment arms To determine time to progression duration of response time to treatment failure and overall survival in each group To evaluate changes from baseline in the Lung Cancer Symptom Scale of patients in each treatment arm
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None